Dashboard
Manage Tickers

NURONeuroMetrix, Inc.


$ -0.06 (-1.49 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
$ 2.66 - $ 6.00
12,774
na
8.14M
$ 1.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

neurometrix-reiterates-its-review-of-strategic-alternatives-in-collaboration-with-a-financial-advisor-the-company-conducted-an-extensive-survey-of-potential-transactions-implemented-a-substantial-reduction-in-force-at-the-end-of-q1-to-lower-operating-expenses-by-over-500k-per-quarter-is-engaged-in-discussions-to-sell-certain-international-assets-that-are-not-central-to-the-companys-core-domestic-focus
NeuroMetrix Reiterates Its Review Of Strat...
08/13/2024 18:49:13

NeuroMetrix, Inc. (NASDAQ:NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strateg...

neurometrix-q2-eps-074-up-from-152-yoy-sales-769148-down-from-165m-yoy
NeuroMetrix Q2 EPS $(0.74) Up From $(1.52)...
08/06/2024 11:09:03

NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(0.74) per share. This is a 51.32 percent increase over losses of $(1.5...

neurometrix-q1-eps-167-down-from-164-yoy-sales-109m-down-from-173m-yoy
NeuroMetrix Q1 EPS $(1.67) Down From $(1.6...
05/15/2024 20:07:04

NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(1.67) per share. This is a 1.83 percent decrease over losses of $(1.64...

neurometrix-q1-revenue-1093m-down-from-1724m-yoy
NeuroMetrix Q1 Revenue $1.093M Down From $...
05/15/2024 20:03:46

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
04/19/2024 16:31:40

neurometrix-appoints-joshua-s-horowitz-as-new-independent-director-co-also-terminates-at-the-market-equity-facility
NeuroMetrix Appoints Joshua S. Horowitz As...
04/19/2024 12:01:21

neurometrix-publishes-study-demonstrating-that-dpncheck-diagnoses-diabetic-peripheral-neuropathy
NeuroMetrix Publishes Study Demonstrating ...
03/14/2024 13:01:18

neurometrix-announces-that-over-2000-patients-with-fibromyalgia-have-been-prescribed-quell-fibromyalgia
NeuroMetrix Announces That Over 2000 Patie...
03/13/2024 13:08:26

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia si...

echo-lake-capital-calls-for-the-liquidation-of-neurometrix-inc-notes-tremendous-destruction-of-shareholder-value-under-cos-leadership-sees-no-reason-for-co-to-remain-public
Echo Lake Capital Calls For The Liquidatio...
03/04/2024 13:08:15

- Stock trades significantly below its net cash per share- Questions the Board's ability and/or desire to create shareholde...

neurometrix-q4-eps-143-down-from-073-yoy-sales-132m-down-from-185m-yoy
NeuroMetrix Q4 EPS $(1.43) Down From $(0.7...
02/22/2024 12:02:42

NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(1.43) per share. This is a decrease over losses of $(0.73) per share f...

earnings-scheduled-for-february-22-2024
Earnings Scheduled For February 22, 2024
02/22/2024 10:27:06

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

neurometrix-13g-filing-shows-rs-fund-lp-reported-a-144-stake-in-the-co-as-of-february-13-2024
NeuroMetrix 13G Filing Shows RS Fund LP Re...
02/20/2024 19:58:49

- SEC Filing 

neurometrix-announces-review-of-strategic-options-to-promote-growth-of-its-quell-neuromodulation-and-dpncheck-neurodiagnostic-businesses-and-to-maximize-shareholder-value
NeuroMetrix Announces Review Of Strategic ...
02/13/2024 14:03:21

NeuroMetrix, Inc. (NASDAQ:NURO), a commercial stage medical device company focused on reducing the impact of neurological disor...

neurometrix-reported-the-recent-presentation-of-data-from-a-clinical-trial-of-quell-wearable-neuromodulation-technology-in-patients-with-post-acute-covid-19-syndrome
NeuroMetrix Reported The Recent Presentati...
12/12/2023 14:03:35

The presentation was made at the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP) annual ...

neurometrix-announces-peer-reviewed-publication-of-phase-2-clinical-trial-showing-that-quell-improves-painful-symptoms-of-chemotherapy-induced-peripheral-neuropathy
NeuroMetrix Announces Peer-Reviewed Public...
12/05/2023 14:01:11

neurometrix-shares-resume-trade
NeuroMetrix Shares Resume Trade
11/22/2023 14:00:29

neurometrix-shares-to-resume-trade-at-900-am-et
NeuroMetrix Shares To Resume Trade At 9:00...
11/22/2023 12:40:11

neurometrix-announces-1-for-8-reverse-stock-split
NeuroMetrix Announces 1-For-8 Reverse Stoc...
11/20/2023 14:01:07

NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effecti...

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
11/10/2023 21:31:01

earnings-scheduled-for-october-26-2023
Earnings Scheduled For October 26, 2023
10/26/2023 11:20:21

Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on re...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION